Overview
Industry Biological Products, (No Diagnostic Substances) Headquarters A6 Incorporated in Ontario, Canada2 Business address 66 Wellington Street West, Suite 5300, Td Bank Tower Box 48, Toronto2 Filer category Non-accelerated filer, Smaller reporting company2 See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025 Financial statements
Income statement Balance sheet Cash flow
Annual Quarterly
Revenue4 5 6 7 3 $0 in 20250 2020: $0 $0 2020 2021: $0 $0 2021 2022: $0 $0 2022 2023: $0 $0 2023 2024: $0 $0 2024 2025: $0 $0 2025 Net income8 4 5 6 7 3 -$25.5M in 2025−3% since 2019 -$80.0M -$60.0M -$40.0M -$20.0M 0 2019: -$26.3M -$26.3M 2019 2020: -$55.2M -$55.2M 2020 +110% 2021: -$65.4M -$65.4M 2021 +18% 2022: -$41.8M -$41.8M 2022 −36% 2023: -$51.2M -$51.2M 2023 +22% 2024: -$25.4M -$25.4M 2024 −50% 2025: -$25.5M -$25.5M 2025 +0% Revenue9 10 11 $0 in Q1 FY20260 Q2 FY2025: $0 $0 Q2 FY2025 Q3 FY2025: $0 $0 Q3 FY2025 Q1 FY2026: $0 $0 Q1 FY2026 Net income9 10 11 -$7.6M in Q1 FY2026+8% since Q2 FY2025 -$8.0M -$6.0M -$4.0M -$2.0M 0 Q2 FY2025: -$7.0M -$7.0M Q2 FY2025 Q3 FY2025: -$5.1M -$5.1M Q3 FY2025 −27% Q1 FY2026: -$7.6M -$7.6M Q1 FY2026 +49% Fiscal year 2019 2020 2021 2022 2023 2024 2025 Revenue $04 $05 $06 $07 $03 $03 Research and development $16.8M8 $29.3M4 $46.0M5 $24.5M6 $33.3M7 $15.1M3 $11.3M3 Income tax $03 $03 Net income -$26.3M8 -$55.2M4 -$65.4M5 -$41.8M6 -$51.2M7 -$25.4M3 -$25.5M3 Earnings per share -$0.735 -$6.806 -$227.437 -$36.383 -$10.413 Earnings per share (diluted) -$0.735 -$6.806 -$227.437 -$36.383 -$10.413
Total assets8 4 5 6 7 3 $10.0M in 2025−90% since 2019 0 $50.0M $100.0M $150.0M 2019: $100.5M $100.5M 2019 2020: $126.3M $126.3M 2020 +26% 2021: $82.5M $82.5M 2021 −35% 2022: $51.0M $51.0M 2022 −38% 2023: $13.0M $13.0M 2023 −75% 2024: $10.1M $10.1M 2024 −22% 2025: $10.0M $10.0M 2025 −1% Total liabilities8 4 5 6 7 3 $37.2M in 2025+468% since 2019 0 $10.0M $20.0M $30.0M $40.0M 2019: $6.5M $6.5M 2019 2020: $7.3M $7.3M 2020 +12% 2021: $8.3M $8.3M 2021 +13% 2022: $13.3M $13.3M 2022 +60% 2023: $15.9M $15.9M 2023 +20% 2024: $14.7M $14.7M 2024 −8% 2025: $37.2M $37.2M 2025 +153% Shareholders’ equity4 5 6 7 3 -$27.2M in 2025-$50.0M 0 $50.0M $100.0M $150.0M 2019: $93.9M $93.9M 2019 2020: $118.9M $118.9M 2020 +27% 2021: $74.2M $74.2M 2021 −38% 2022: $37.7M $37.7M 2022 −49% 2023: -$2.9M -$2.9M 2023 2024: -$4.5M -$4.5M 2024 +57% 2025: -$27.2M -$27.2M 2025 +498% Cash8 4 5 6 7 3 $935.0K in 2025−99% since 2019 0 $50.0M $100.0M $150.0M 2019: $79.8M $79.8M 2019 2020: $117.4M $117.4M 2020 +47% 2021: $39.1M $39.1M 2021 −67% 2022: $37.0M $37.0M 2022 −5% 2023: $9.3M $9.3M 2023 −75% 2024: $6.2M $6.2M 2024 −34% 2025: $935.0K $935.0K 2025 −85% Total assets9 10 11 $10.7M in Q1 FY2026+92% since Q2 FY2025 0 $5.0M $10.0M $15.0M Q2 FY2025: $5.6M $5.6M Q2 FY2025 Q3 FY2025: $6.3M $6.3M Q3 FY2025 +13% Q1 FY2025: $10.0M $10.0M Q1 FY2025 +58% Q1 FY2026: $10.7M $10.7M Q1 FY2026 +7% Total liabilities9 10 11 $45.4M in Q1 FY2026+127% since Q2 FY2025 0 $20.0M $40.0M $60.0M Q2 FY2025: $20.0M $20.0M Q2 FY2025 Q3 FY2025: $25.8M $25.8M Q3 FY2025 +29% Q1 FY2025: $37.2M $37.2M Q1 FY2025 +44% Q1 FY2026: $45.4M $45.4M Q1 FY2026 +22% Shareholders’ equity9 10 11 -$34.7M in Q1 FY2026+141% since Q2 FY2025 -$40.0M -$30.0M -$20.0M -$10.0M 0 Q2 FY2025: -$14.4M -$14.4M Q2 FY2025 Q3 FY2025: -$19.4M -$19.4M Q3 FY2025 +35% Q1 FY2025: -$27.2M -$27.2M Q1 FY2025 +40% Q1 FY2026: -$34.7M -$34.7M Q1 FY2026 +28% Cash9 10 $613.0K in Q3 FY2025+11% since Q2 FY2025 0 $200.0K $400.0K $600.0K $800.0K Q2 FY2025: $553.0K $553.0K Q2 FY2025 Q3 FY2025: $613.0K $613.0K Q3 FY2025 +11% Fiscal year 2019 2020 2021 2022 2023 2024 2025 Cash $79.8M8 $117.4M4 $39.1M5 $37.0M6 $9.3M7 $6.2M3 $935.0K3 Current assets $98.8M8 $125.1M4 $81.7M5 $49.5M6 $11.9M7 $9.5M3 $6.4M3 Total assets $100.5M8 $126.3M4 $82.5M5 $51.0M6 $13.0M7 $10.1M3 $10.0M3 Current liabilities $5.5M8 $6.8M4 $8.2M5 $12.3M6 $15.3M7 $4.5M3 $9.3M3 Total liabilities $6.5M8 $7.3M4 $8.3M5 $13.3M6 $15.9M7 $14.7M3 $37.2M3 Shareholders’ equity $93.9M4 $118.9M5 $74.2M6 $37.7M7 -$2.9M3 -$4.5M3 -$27.2M3 Shares outstanding 76.1M shares8 88.9M shares4 92.2M shares5 6.2M shares6 264.7K shares7 2.0M shares3 2.6M shares3
Cash from operations8 4 5 6 7 3 -$22.0M in 2025+2% since 2019 -$60.0M -$40.0M -$20.0M 0 2019: -$21.6M -$21.6M 2019 2020: -$33.9M -$33.9M 2020 +57% 2021: -$43.3M -$43.3M 2021 +28% 2022: -$32.3M -$32.3M 2022 −25% 2023: -$44.6M -$44.6M 2023 +38% 2024: -$36.0M -$36.0M 2024 −19% 2025: -$22.0M -$22.0M 2025 −39% Capital spending8 4 5 6 7 3 $0 in 20250 $100.0K $200.0K $300.0K 2019: $102.0K $102.0K 2019 2020: $79.0K $79.0K 2020 −23% 2021: $212.0K $212.0K 2021 +168% 2022: $24.0K $24.0K 2022 −89% 2023: $29.0K $29.0K 2023 +21% 2024: $5.0K $5.0K 2024 −83% 2025: $0 $0 2025 Free cash flow8 4 5 6 7 3 -$22.0M in 2025+2% since 2019 -$60.0M -$40.0M -$20.0M 0 2019: -$21.7M -$21.7M 2019 2020: -$34.0M -$34.0M 2020 +57% 2021: -$43.5M -$43.5M 2021 +28% 2022: -$32.3M -$32.3M 2022 −26% 2023: -$44.6M -$44.6M 2023 +38% 2024: -$36.0M -$36.0M 2024 −19% 2025: -$22.0M -$22.0M 2025 −39% Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Fiscal year 2019 2020 2021 2022 2023 2024 2025 Cash from operations -$21.6M8 -$33.9M4 -$43.3M5 -$32.3M6 -$44.6M7 -$36.0M3 -$22.0M3 Capital spending $102.0K8 $79.0K4 $212.0K5 $24.0K6 $29.0K7 $5.0K3 $03 Free cash flow -$21.7M -$34.0M -$43.5M -$32.3M -$44.6M -$36.0M -$22.0M
Compare Aptose Biosciences Inc. with another company
Former names
Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.) Sep 8, 2014 to Nov 26, 20142 LORUS THERAPEUTICS INC Jul 10, 2002 to Sep 2, 20142 IMUTEC PHARMA INC Feb 14, 1997 to Mar 24, 19982
Recent filings
Jul 2, 2026 4 Jul 1, 2026 8-K Jul 1, 2026 8-K Jul 1, 2026 4 Jul 1, 2026 4 Jul 1, 2026 4 Jul 1, 2026 4 Jul 1, 2026 4 Jul 1, 2026 4 Jul 1, 2026 4 Jun 15, 2026 8-K May 29, 2026 8-K May 13, 2026 8-K May 13, 2026 10-Q Apr 30, 2026 8-K Every filing from the last three years, summarized . The full record is on SEC EDGAR.1
